CureVac NV (CVAC)

Currency in USD
4.660
-0.010(-0.21%)
Real-time Data·
Showing CureVac NV historical data. For real-time data please try another search
Fair Value
Day's Range
4.5704.665
52 wk Range
2.4755.720
Key Statistics
Prev. Close
4.66
Open
4.57
Day's Range
4.57-4.665
52 wk Range
2.475-5.72
Volume
1.15M
Average Volume (3m)
1.12M
1-Year Change
-0.4274%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CVAC Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
5.406
Upside
+16.02%
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.

CureVac NV News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

1 Buy
3 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 5.406
(+16.02% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

CureVac NV SWOT Analysis


mRNA Pioneer's Path
Explore CureVac's journey as an mRNA therapy innovator, navigating financial challenges while advancing its oncology pipeline and maintaining a strong cash position
Financial Fortitude
Delve into CureVac's robust financial strategy, including its cash runway extending to 2028 and strategic cost-saving measures aimed at long-term sustainability
Oncology Breakthroughs
Discover CureVac's promising oncology pipeline, featuring encouraging preliminary results for its CVGBM cancer vaccine and plans for future clinical candidates
Market Outlook
Learn about analyst perspectives on CureVac, with price targets around $16, reflecting cautious optimism amidst a competitive mRNA therapy landscape
Read full SWOT analysis

CureVac NV Earnings Call Summary for Q3/2024

  • Q3 revenue soared to €493.9M, driven by €1.45B GSK licensing deal; strong cash position of €551M reported
  • Strategic shift to oncology and infectious diseases; 30% workforce reduction planned to enhance efficiency
  • Advancing mRNA cancer vaccines; new program for urinary tract infections shows promise in preclinical studies
  • Operating expenses expected to rise 30%+ in 2024; aim to decrease by over 30% starting 2025
  • Axel Malkomes appointed as new CFO; U.S. court case scheduled for March 2025 regarding ongoing litigation
Last Updated: 11/13/2024, 06:00 PM
Read Full Transcript

Earnings

Latest Release
Apr 29, 2026
EPS / Forecast
-- / -0.09
Revenue / Forecast
-- / 13.35M
EPS Revisions
Last 90 days

CVAC Income Statement

Compare CVAC to Peers and Sector

Metrics to compare
CVAC
Peers
Sector
Relationship
P/E Ratio
0.0x0.0x−0.4x
PEG Ratio
0.000.000.00
Price/Book
0.0x0.0x2.6x
Price / LTM Sales
0.0x0.0x3.0x
Upside (Analyst Target)
0.0%0.0%51.8%
Fair Value Upside
Unlock0.0%7.2%Unlock

People Also Watch

208.09
CBRS
-3.73%
171.14
SPCX
+4.23%
9.5050
QUBT
-4.18%
272.55
CRDO
+10.94%
258.69
GLW
+1.17%
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.